Testing romiplostim for low platelets in breast cancer chemo
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new form of romiplostim (a drug that boosts platelets) in breast cancer patients whose platelet counts have dropped due to chemotherapy. It aims to see if it can safely raise platelet levels to reduce bleeding risk and allow chemo to continue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a confirmed breast cancer diagnosis
- Your platelet count is below 75 (a measure of platelet level) due to chemotherapy
- You have not used romiplostim or a similar drug in the last 3 months
- You are willing to use reliable birth control if you could become pregnant
- You have not had other serious health issues like severe heart disease, brain metastases, or liver/kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
This study tests a medicine called romiplostim N01 to see if it can prevent low platelet counts caused by chemotherapy in breast cancer patients. It may help reduce the risk of bleeding and allow you to complete your chemotherapy on time.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This trial tests a drug called Romiplostim to help raise low platelet counts caused by leukemia treatment. It is for adults with leukemia whose platelets are below 50 and who may benefit from this therapy.
Hear when a new Romiplostim N01 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.